Anzeige
Mehr »
Login
Freitag, 17.01.2025 Börsentäglich über 12.000 News von 682 internationalen Medien
Letzte Chance, bevor die Bohrer dieses "Monster"-Vorkommen bei einem 13-Millionen-Unternehmen ansteuern
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
240 Leser
Artikel bewerten:
(0)

Capital for Colleagues plc - Director/PDMR Shareholdings

Finanznachrichten News

Capital for Colleagues plc - Director/PDMR Shareholdings

PR Newswire

Capital for Colleagues plc / EPIC: CFCP / Market: AQSE / Sector: Investment

23 September 2021

CAPITAL FOR COLLEAGUES PLC

('Capital for Colleagues', 'C4C' or the 'Company')

DIRECTOR/PDMR SHAREHOLDINGS

Capital for Colleagues, the investment vehicle focused on opportunities in the Employee Owned Business ('EOB') sector, has been notified that C4C SIP Trustee Limited has allocated a total of 15,780 ordinary shares of 40p each in the Company ('Ordinary Shares') to participants in the Company's Share Incentive Plan at a price of 47.5p per share.

Alistair Currie, Chief Executive Officer of the Company, is interested in 4,735 of the Ordinary Shares allocated by the Share Incentive Plan and his interest in the Company's issued share capital is now 577,104 Ordinary Shares, representing 3.74% of the Company's issued share capital.

John Lewis, Finance Director of the Company, is interested in 4,735 of the Ordinary Shares allocated by the Share Incentive Plan and his interest in the Company's issued share capital is now 289,289 Ordinary Shares, representing 1.87% of the Company's issued share capital.

The Directors of the Company are responsible for the contents of this announcement.

**ENDS**

For further information, please visit www.capitalforcolleagues.com or contact:


CAPITAL FOR COLLEAGUES PLC
Richard Bailey, Chairman
Alistair Currie, Chief Executive

01985 201 980
PETERHOUSE CAPITAL LIMITED
Mark Anwyl
020 7469 0930

Capital for Colleagues

Capital for Colleagues is an investment company focused on the UK EOB sector. The Company has a proven management team, with a wide network of contacts and affiliates, as well as established access to investment opportunities, enabling the Company to execute its strategy and capitalise on EOB-focused investment opportunities. In addition, the Company educates and assists companies that are looking to launch employee ownership schemes, advising them, amongst other things, on how to secure investment and achieve their objectives.

Market Abuse Regulation (MAR) Disclosure

This announcement contains inside information for the purposes of Article 7 of the Market Abuse Regulation EU 596/2014 as it forms part of retained EU law (as defined in the European Union (Withdrawal) Act 2018).

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them.
1Details of the person discharging managerial responsibilities / person closely associated
a)NameAlistair Currie
2Reason for the notification
a)Position/statusChief Executive of Capital for Colleagues plc
b)Initial notification /Amendment
Initial
3Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)NameCapital for Colleagues plc
b)LEI213800K2JRG9LQKQTM98
4Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)Description of the financial instrument, type of instrument
Identification code
Ordinary Shares of 40p each


ISIN: GB00BGCZ2V99
b)Nature of the transactionAllocation of Ordinary Shares by SIP Trustee
c)Price(s) and volume(s)4,735 Ordinary Shares at 47.5p per share
d)Aggregated information
- Aggregated volume
- Price


n/a (single transaction)
e)Date of the transaction23 September 2021
f)Place of the transactionOff market transfer

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them.
1Details of the person discharging managerial responsibilities / person closely associated
a)NameJohn Lewis
2Reason for the notification
a)Position/statusDirector of Capital for Colleagues plc
b)Initial notification /Amendment
Initial
3Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)NameCapital for Colleagues plc
b)LEI213800K2JRG9LQKQTM98
4Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)Description of the financial instrument, type of instrument
Identification code
Ordinary Shares of 40p each


ISIN: GB00BGCZ2V99
b)Nature of the transactionAllocation of Ordinary Shares by SIP Trustee
c)Price(s) and volume(s)4,735 Ordinary Shares at 47.5p per share
d)Aggregated information
- Aggregated volume
- Price


n/a (single transaction)
e)Date of the transaction23 September 2021
f)Place of the transactionOff market transfer
© 2021 PR Newswire
Gewinner im Megamarkt
Biotechnologie ist eine der bedeutendsten Zukunftstechnologien unserer Zeit. Zahlreiche Biotechnologie- und Pharmakonzerne haben sich unter anderem dem Kampf gegen Tumorerkrankungen verschrieben. Der weltweite Markt für Krebsmedikamente verzeichnet ein stetiges Wachstum. Für das Jahr 2025 wird ein Umsatz von etwa 190,3 Milliarden Euro prognostiziert, mit einer erwarteten jährlichen Wachstumsrate von 6,42% bis 2029, was zu einem geschätzten Marktvolumen von 244,1 Milliarden Euro führen würde.

Wir haben 3 aussichtsreiche Biotechnologieaktien mit Schwerpunkt Erforschung und Entwicklung von Wirkstoffen gegen Tumorerkrankungen ausfindig gemacht, die in den kommenden Monaten und Jahren erhebliches Aufwärtspotenzial versprechen und Vervielfachungspotenzial besitzen.

Fordern Sie jetzt unseren neuen kostenlosen Spezialreport an und erfahren Sie, welche 3 Biotech-Aktien durchstarten und zu Ihrem Börsenerfolg in 2025 beitragen könnten!
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.